Vanguard Group Inc Affimed N.V. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $416,993 - $790,092	-731,567 Reduced 34.16%	1,410,249 $846,000
Q1 2023 May 15, 2023	BUY	$0.66 - $1.29 $18,775 - $36,696	28,447 Added 1.35%	2,141,816 $1.61 Million
Q4 2022 Feb 10, 2023	BUY	$1.1 - $2.45 $786,651 - $1.75 Million	715,138 Added 51.15%	2,113,369 $2.62 Million
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $335,665 - $568,576	171,258 Added 13.96%	1,398,231 $2.88 Million
Q2 2022 Aug 12, 2022	SELL	$2.27 - $4.86 $362,582 - $776,278	-159,728 Reduced 11.52%	1,226,973 $3.4 Million
Q1 2022 May 13, 2022	BUY	$3.69 - $5.65 $20,291 - $31,069	5,499 Added 0.4%	1,386,701 $6.06 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $75,926 - $99,962	14,139 Added 1.03%	1,381,202 $7.63 Million
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $2.23 Million - $3.02 Million	402,630 Added 41.75%	1,367,063 $8.45 Million
Q2 2021 Aug 13, 2021	BUY	$7.78 - $11.4 $7.5 Million - $11 Million	964,433 New	964,433 $8.2 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.